TY - JOUR
T1 - Responsible Radionuclide Cancer Care
AU - Turner, J. Harvey
PY - 2021/10
Y1 - 2021/10
N2 - The landscape of nuclear oncology is rapidly changing. The advent of molecular radionuclide theranostics, multidisciplinary tumor board decision making, artificial intelligence and radiomics interpretation of diagnostic imaging, evolution of pharmacogenomics prediction of tumor response, and regulatory requirements for prospective individual dosimetry are just some of the elements which are broadening the essence of physician responsibility. The burgeoning knowledge base essential for mastering the emergent technologies, and their profound effect on moral philosophic aspects of provision of cancer care, are challenging. The new relationship of the theranostic nuclear physician with respect to shared care of the individual patient, particularly with regard to transparency, accountability, and responsibility for targeted radionuclide diagnosis and therapy of cancer, will be explored in this update.
AB - The landscape of nuclear oncology is rapidly changing. The advent of molecular radionuclide theranostics, multidisciplinary tumor board decision making, artificial intelligence and radiomics interpretation of diagnostic imaging, evolution of pharmacogenomics prediction of tumor response, and regulatory requirements for prospective individual dosimetry are just some of the elements which are broadening the essence of physician responsibility. The burgeoning knowledge base essential for mastering the emergent technologies, and their profound effect on moral philosophic aspects of provision of cancer care, are challenging. The new relationship of the theranostic nuclear physician with respect to shared care of the individual patient, particularly with regard to transparency, accountability, and responsibility for targeted radionuclide diagnosis and therapy of cancer, will be explored in this update.
KW - accountability
KW - artificial intelligence
KW - multidisciplinary tumor board responsibility
KW - personalized dosimetry
KW - phronesis
KW - theranostics
UR - http://www.scopus.com/inward/record.url?scp=85117218276&partnerID=8YFLogxK
U2 - 10.1089/cbr.2021.0152
DO - 10.1089/cbr.2021.0152
M3 - Article
C2 - 34339288
AN - SCOPUS:85117218276
SN - 1084-9785
VL - 36
SP - 617
EP - 623
JO - Cancer Biotherapy and Radiopharmaceuticals
JF - Cancer Biotherapy and Radiopharmaceuticals
IS - 8
ER -